Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Navidea Biopharmaceuticals Inc (NY: NAVB ) N/A UNCHANGED Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Navidea Biopharmaceuticals Inc < Previous 1 2 3 Next > Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations January 26, 2024 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release December 01, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock October 05, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel August 10, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities July 31, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination July 28, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer July 27, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down July 13, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets June 30, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock June 16, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment June 16, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update June 07, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice June 02, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down June 01, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market May 22, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer May 11, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications May 08, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit April 27, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694 April 13, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down March 30, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results March 21, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update March 15, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline January 03, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Files Appeal in CRG Case November 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis November 28, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results November 14, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting November 07, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update November 04, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting October 05, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders September 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
